Clinical trial
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
NCT03323437 is registered in ClinicalTrials.gov with Weill Medical College of Cornell University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia
- Lead sponsor
- Weill Medical College of Cornell University
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 15, 2017
- Completion date
- May 31, 2023
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.